Chemed Corporation $CHE Shares Sold by Vest Financial LLC

Key Points

• Vest Financial reduced its Chemed stake by 28.3% in the third quarter, selling 3,523 shares and retaining 8,932 shares valued at approximately $4.5 million. Institutional investors and hedge funds collectively own 95.85% of CHE.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and an average price target of $554.60; individual targets range from $548 to $650.
• Chemed reported stronger-than-expected quarterly results, with EPS of $6.06 and revenue of $673.25 million, while raising its quarterly dividend from $0.60 to $0.70 per share.

Vest Financial LLC cut its holdings in Chemed Corporation (NYSE:CHE - Free Report) by 28.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,932 shares of the company's stock after selling 3,523 shares during the quarter. Vest Financial LLC owned about 0.07% of Chemed worth $4,511,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of CHE. BlackRock Inc. purchased a new position in Chemed during the second quarter valued at approximately $691,290,000. First Trust Advisors LP lifted its stake in shares of Chemed by 24.7% in the 1st quarter. First Trust Advisors LP now owns 236,392 shares of the company's stock valued at $89,295,000 after purchasing an additional 46,791 shares during the period. Copeland Capital Management LLC boosted its holdings in Chemed by 7.6% during the first quarter. Copeland Capital Management LLC now owns 147,957 shares of the company's stock worth $55,889,000 after buying an additional 10,406 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Chemed by 7.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 107,215 shares of the company's stock worth $40,481,000 after buying an additional 7,807 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Chemed during the 2nd quarter valued at about $48,255,000. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on CHE. Bank of America restated a "neutral" rating on shares of Chemed in a report on Wednesday, July 29th. Oppenheimer increased their price target on Chemed from $500.00 to $590.00 and gave the stock an "outperform" rating in a report on Friday, July 31st. Weiss Ratings upgraded Chemed from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. Royal Bank Of Canada boosted their price target on shares of Chemed from $436.00 to $548.00 and gave the stock a "sector perform" rating in a research note on Thursday, July 30th. Finally, UBS Group assumed coverage on shares of Chemed in a research report on Friday, September 25th. They issued a "buy" rating and a $650.00 price target for the company. Two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $554.60.

Insider Activity

In other news, CEO Kevin McNamara sold 2,000 shares of Chemed stock in a transaction on Monday, September 28th. The shares were sold at an average price of $513.45, for a total transaction of $1,026,900.00. Following the completion of the sale, the chief executive officer directly owned 66,418 shares of the company's stock, valued at approximately $34,102,322.10. The trade was a 2.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Patrick Grace sold 190 shares of the business's stock in a transaction on Friday, July 31st. The stock was sold at an average price of $532.00, for a total transaction of $101,080.00. Following the transaction, the director owned 3,533 shares of the company's stock, valued at approximately $1,879,556. The trade was a 5.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 9,190 shares of company stock worth $4,833,160. 3.33% of the stock is currently owned by corporate insiders.

Chemed Stock Performance

Shares of CHE opened at $512.72 on Friday. The stock has a 50-day simple moving average of $514.99 and a 200-day simple moving average of $475.86. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91. The stock has a market capitalization of $6.70 billion, a PE ratio of 24.24, a PEG ratio of 2.09 and a beta of 0.51. Chemed Corporation has a 1 year low of $365.20 and a 1 year high of $557.00.

Chemed (NYSE:CHE - Get Free Report) last issued its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, beating the consensus estimate of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The firm had revenue of $673.25 million for the quarter, compared to analysts' expectations of $665.04 million. During the same quarter last year, the company earned $4.27 earnings per share. The firm's revenue was up 8.8% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, analysts predict that Chemed Corporation will post 23.55 earnings per share for the current fiscal year.

Chemed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Monday, August 17th. This is a positive change from Chemed's previous quarterly dividend of $0.60. Chemed's dividend payout ratio (DPR) is 14.06%.

Chemed Profile

Chemed Corporation NYSE: CHE is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients' homes, hospice inpatient units, hospitals, nursing facilities and other care settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.